Cargando…

Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study

INTRODUCTION: Anemia has long been associated with poor prognosis in patients with cervical cancer. Recently, additional hematologic parameters have emerged as potential indicators of worse outcome in this patient group. In a cohort of cervical cancer patients treated with chemoradiotherapy (CRT) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Koulis, Theodora A., Kornaga, Elizabeth N., Banerjee, Robyn, Phan, Tien, Ghatage, Prafull, Magliocco, Anthony M., Lees-Miller, Susan P., Doll, Corinne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833917/
https://www.ncbi.nlm.nih.gov/pubmed/29594208
http://dx.doi.org/10.1016/j.ctro.2017.05.001
_version_ 1783303566703722496
author Koulis, Theodora A.
Kornaga, Elizabeth N.
Banerjee, Robyn
Phan, Tien
Ghatage, Prafull
Magliocco, Anthony M.
Lees-Miller, Susan P.
Doll, Corinne M.
author_facet Koulis, Theodora A.
Kornaga, Elizabeth N.
Banerjee, Robyn
Phan, Tien
Ghatage, Prafull
Magliocco, Anthony M.
Lees-Miller, Susan P.
Doll, Corinne M.
author_sort Koulis, Theodora A.
collection PubMed
description INTRODUCTION: Anemia has long been associated with poor prognosis in patients with cervical cancer. Recently, additional hematologic parameters have emerged as potential indicators of worse outcome in this patient group. In a cohort of cervical cancer patients treated with chemoradiotherapy (CRT) and brachytherapy, we report on the prognostic significance of hematologic parameters including anemia, leukocytosis, neutrophil to lymphocyte ratio (NLR), and thrombocytosis, the effect of combining anemia with other hematologic parameters, and the effect of changes in hemoglobin levels during treatment. MATERIALS AND METHODS: Two-hundred fifty-seven cervical cancer patients were retrospectively identified from a single cancer institution’s database. Hematologic parameters were categorized as: anemia (hemoglobin ≤115 g/L), leukocytosis (white blood cell count >10 × 10(9)/L), thrombocytosis (platelets >400 × 10(9)/L), and NLR (ratio >5). The association between clinical factors and hematologic parameters on progression-free survival (PFS) and overall survival (OS) were assessed at 5 years. RESULTS: At 5 years, both pre-treatment anemia (PFS: 60% vs 34%, p < 0.0001; OS: 68% vs 41%, p < 0.0001) and on-treatment anemia (PFS: 62% vs 40%, p < 0.0001; OS: 70% vs 48%, p < 0.0001) were significantly associated with worse survival. This adverse effect on 5-year PFS and OS was increased in patients with both pre-treatment anemia and leukocytosis (PFS: 72% vs 42%, p < 0.0001; OS: 68% vs 37%, p < 0.0001) and pre-treatment anemia and elevated NLR (PFS: 61% vs 30%, p < 0.0001; OS: 68% vs 37%, p < 0.0001). Five-year PFS (50% vs 31%) and OS (60% vs 36%) was better in patients whose pre-treatment anemia improved to normal hemoglobin levels on treatment vs those patients who were anemic both pre- and on-treatment. CONCLUSION: Pre-treatment and on-treatment anemia were significant, independent predictors of worse PFS and OS. Anemia and other hematologic parameters remain prognostic markers for cervical cancer patients. Improvement in PFS and OS was seen in patients with normalization of hemoglobin.
format Online
Article
Text
id pubmed-5833917
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-58339172018-03-28 Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study Koulis, Theodora A. Kornaga, Elizabeth N. Banerjee, Robyn Phan, Tien Ghatage, Prafull Magliocco, Anthony M. Lees-Miller, Susan P. Doll, Corinne M. Clin Transl Radiat Oncol Article INTRODUCTION: Anemia has long been associated with poor prognosis in patients with cervical cancer. Recently, additional hematologic parameters have emerged as potential indicators of worse outcome in this patient group. In a cohort of cervical cancer patients treated with chemoradiotherapy (CRT) and brachytherapy, we report on the prognostic significance of hematologic parameters including anemia, leukocytosis, neutrophil to lymphocyte ratio (NLR), and thrombocytosis, the effect of combining anemia with other hematologic parameters, and the effect of changes in hemoglobin levels during treatment. MATERIALS AND METHODS: Two-hundred fifty-seven cervical cancer patients were retrospectively identified from a single cancer institution’s database. Hematologic parameters were categorized as: anemia (hemoglobin ≤115 g/L), leukocytosis (white blood cell count >10 × 10(9)/L), thrombocytosis (platelets >400 × 10(9)/L), and NLR (ratio >5). The association between clinical factors and hematologic parameters on progression-free survival (PFS) and overall survival (OS) were assessed at 5 years. RESULTS: At 5 years, both pre-treatment anemia (PFS: 60% vs 34%, p < 0.0001; OS: 68% vs 41%, p < 0.0001) and on-treatment anemia (PFS: 62% vs 40%, p < 0.0001; OS: 70% vs 48%, p < 0.0001) were significantly associated with worse survival. This adverse effect on 5-year PFS and OS was increased in patients with both pre-treatment anemia and leukocytosis (PFS: 72% vs 42%, p < 0.0001; OS: 68% vs 37%, p < 0.0001) and pre-treatment anemia and elevated NLR (PFS: 61% vs 30%, p < 0.0001; OS: 68% vs 37%, p < 0.0001). Five-year PFS (50% vs 31%) and OS (60% vs 36%) was better in patients whose pre-treatment anemia improved to normal hemoglobin levels on treatment vs those patients who were anemic both pre- and on-treatment. CONCLUSION: Pre-treatment and on-treatment anemia were significant, independent predictors of worse PFS and OS. Anemia and other hematologic parameters remain prognostic markers for cervical cancer patients. Improvement in PFS and OS was seen in patients with normalization of hemoglobin. Elsevier 2017-06-12 /pmc/articles/PMC5833917/ /pubmed/29594208 http://dx.doi.org/10.1016/j.ctro.2017.05.001 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Koulis, Theodora A.
Kornaga, Elizabeth N.
Banerjee, Robyn
Phan, Tien
Ghatage, Prafull
Magliocco, Anthony M.
Lees-Miller, Susan P.
Doll, Corinne M.
Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study
title Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study
title_full Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study
title_fullStr Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study
title_full_unstemmed Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study
title_short Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study
title_sort anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: a retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833917/
https://www.ncbi.nlm.nih.gov/pubmed/29594208
http://dx.doi.org/10.1016/j.ctro.2017.05.001
work_keys_str_mv AT koulistheodoraa anemialeukocytosisandthrombocytosisasprognosticfactorsinpatientswithcervicalcancertreatedwithradicalchemoradiotherapyaretrospectivecohortstudy
AT kornagaelizabethn anemialeukocytosisandthrombocytosisasprognosticfactorsinpatientswithcervicalcancertreatedwithradicalchemoradiotherapyaretrospectivecohortstudy
AT banerjeerobyn anemialeukocytosisandthrombocytosisasprognosticfactorsinpatientswithcervicalcancertreatedwithradicalchemoradiotherapyaretrospectivecohortstudy
AT phantien anemialeukocytosisandthrombocytosisasprognosticfactorsinpatientswithcervicalcancertreatedwithradicalchemoradiotherapyaretrospectivecohortstudy
AT ghatageprafull anemialeukocytosisandthrombocytosisasprognosticfactorsinpatientswithcervicalcancertreatedwithradicalchemoradiotherapyaretrospectivecohortstudy
AT maglioccoanthonym anemialeukocytosisandthrombocytosisasprognosticfactorsinpatientswithcervicalcancertreatedwithradicalchemoradiotherapyaretrospectivecohortstudy
AT leesmillersusanp anemialeukocytosisandthrombocytosisasprognosticfactorsinpatientswithcervicalcancertreatedwithradicalchemoradiotherapyaretrospectivecohortstudy
AT dollcorinnem anemialeukocytosisandthrombocytosisasprognosticfactorsinpatientswithcervicalcancertreatedwithradicalchemoradiotherapyaretrospectivecohortstudy